Published in Diabetes Care on May 01, 2016
Empagliflozin: Novel antidiabetes and pro-cardiac drug. Indian J Anaesth (2017) 0.91
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use. Diabetes Ther (2017) 0.83
Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect. Indian J Endocrinol Metab (2016) 0.78
Getting to the "Heart" of the Matter on Diabetic Cardiovascular Disease: "Thanks for the Memory". Diabetes Care (2016) 0.78
Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study. Cardiovasc Diabetol (2016) 0.76
Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes. Diabetes Care (2016) 0.75
Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond. Drugs Context (2016) 0.75
Metabolic Recovery of the Failing Heart: Emerging Therapeutic Options. Methodist Debakey Cardiovasc J (2017) 0.75
Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial. Cardiovasc Diabetol (2017) 0.75
Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes. Ther Clin Risk Manag (2017) 0.75
Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure. Vasc Health Risk Manag (2016) 0.75
Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol (2017) 0.75
Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME. Nat Rev Endocrinol (2017) 0.75
Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus. Diabetes Ther (2016) 0.75
Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis. Cardiovasc Diabetol (2017) 0.75
Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial? Mol Cell Biochem (2017) 0.75
Combination Therapy With GLP-1 Receptor Agonist and SGLT2 Inhibitor. Diabetes Obes Metab (2017) 0.75
Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus. Diabetes Metab Syndr Obes (2017) 0.75
The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial. BMJ Open (2017) 0.75
Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes. Pharmacotherapy (2017) 0.75
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med (2008) 35.49
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 29.32
Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med (2008) 25.70
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med (2015) 18.66
Uric acid and cardiovascular risk. N Engl J Med (2008) 12.20
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation (2006) 10.05
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation (2002) 6.22
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet (2015) 4.65
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med (2016) 4.52
Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension (2007) 4.20
The theoretical bases of indirect calorimetry: a review. Metabolism (1988) 4.12
The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol (2007) 4.04
Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med (2015) 3.67
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest (2014) 3.31
Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia (2010) 3.17
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest (2014) 3.10
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med (2015) 2.85
Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab (2012) 2.58
Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev (2011) 2.23
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Am Heart J (2013) 2.12
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab (2013) 1.85
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol (2014) 1.75
Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care (2001) 1.56
Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med (1997) 1.53
Association of Cardiometabolic Multimorbidity With Mortality. JAMA (2015) 1.32
Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol (2013) 1.29
Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med (2013) 1.23
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol (2012) 1.22
Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord (2014) 1.15
Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther (2013) 1.11
Cardiovascular morbidity and mortality of the metabolic syndrome. Med Clin North Am (2007) 1.07
Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. Nat Rev Cardiol (2014) 1.02
Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia (2013) 1.00
Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002. Am J Kidney Dis (2014) 0.93
Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. Diabetes Obes Metab (2014) 0.92
Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction. Mol Metab (2014) 0.90
Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects. Atherosclerosis (2010) 0.90
Relationship Between Left Ventricular Structural and Metabolic Remodeling in Type 2 Diabetes. Diabetes (2015) 0.88
Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiol Renal Physiol (2015) 0.83
Expression of SGLT1 in Human Hearts and Impairment of Cardiac Glucose Uptake by Phlorizin during Ischemia-Reperfusion Injury in Mice. PLoS One (2015) 0.81
Understanding EMPA-REG OUTCOME. Lancet Diabetes Endocrinol (2015) 0.79
Pioglitazone lowers blood pressure in hypertensive patients with type 2 diabetes mellitus : an open, multicentre, observational study. Clin Drug Investig (2005) 0.78
Low-dose intravenous glucagon has no effect on myocardial contractility in normal man. An echocardiographic study. Scand J Clin Lab Invest (1988) 0.78
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet (2013) 2.66
Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes Care (2014) 2.04
Chronic reduction of plasma free fatty acid improves mitochondrial function and whole-body insulin sensitivity in obese and type 2 diabetic individuals. Diabetes (2013) 1.54
Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum. Diabetes Care (2014) 1.07
Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists. Diabetes Care (2015) 0.81
Response to comment on Home et al. Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes care 2014;37:1499-1508. Diabetes Care (2014) 0.75
Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes Care (2017) 0.75